Professor Paul Ellis

Consultant Medical Oncologist


A nationally and internationally recognised opinion leader in the field of breast cancer

Professor Paul Ellis is Consultant Medical Oncologist at Guy’s Hospital and Professor of cancer Medicine at Kings College London. He was also a founding partner of the London Oncology Clinic.

He has authored over 100 peer-reviewed scientific papers, with a particular focus on breast cancer research. Professor Ellis has been on the editorial board of a number of oncology journals, including the Journal of Clinical Oncology. He is regularly asked to give plenary lectures, national and internationally, at breast cancer meetings and congresses.

His major breast cancer research interests include novel clinical research strategies in the adjuvant and neoadjuvant setting, with an emphasis on the integration of new therapies. He has been at the forefront of new drug trials for over two decades, including molecular focused treatments.

Professor Ellis prides himself on taking a holistic approach to breast cancer medicine. He works closely with other clinical colleagues within a multidisciplinary team environment. In addition his clinical team involves other healthcare providers including nutritionists and massage therapists.

Professional background


Professor Ellis studied medicine at Otago University in New Zealand before completing his fellowship in Medical Oncology and his postgraduate Doctor of Medicine research degree at London's Royal Marsden Hospital. He was awarded the inaugural ASCO Fellowship Award in 1996. He was then appointed as consultant Medical Oncologist at Guy’s Hospital in 1997. Between 2003 and 2006 he was Head of Medical Oncology at Guy's. He subsequently took up the role of Director for the South East London Cancer Network.

In 2010 he was awarded a Personal Chair and became Professor of cancer Medicine at King's College London. He has also been the lead for breast cancer research and more recently the clinical lead in driving the development of the new Guy’s Hospital cancer centre.

Professor Ellis has also been heavily involved in clinical research in UK and Europe. He was involved in setting up the UK Breast Intergroup, which brings together leading researchers around the UK for regular forums. He has been the principal investigator on a number of national and international clinical rails, including the National UK Adjuvant Chemotherapy (PACT), the global Kamilla and Mary-Anne trials.

Professor Ellis was also co-chair of the UK Department of Health Advisory Committee for the development of national treatment guidelines for the use of Adjuvant Trastuzumab. He has been an expert advisor to NICE and the National Cancer Drugs Fund with regards to the implementation of new therapies into the NHS.

Services provided to HCA


Professor Ellis provides medical advisory services to HCA and is a Medical Director for HCA's Leaders in Oncology Care. In his role, Professor Ellis leads interactions with hospital medical staff and the hospital leadership team to assist by providing medical advice and promoting high quality, cost effective care.

In his role, he contributes to the strategy, policies and decision making regarding oncology treatments and advises HCA to ensure that care provided within the facility is appropriate and efficient. In his role, Professor Ellis advises on initiatives to drive clinical standards by providing professional advice on clinical governance matters and ensuring the adoption of those by colleagues in the oncology area.

In addition, he works with medical insurance companies, GPs, other relevant local NHS contacts, and patients to educate and advise on relevant clinical updates to treatments in oncology available in the facility. Furthermore, he advises on the accuracy of literature that may be published regarding relevant services. He will also advise on how to make the patient referral smooth to reduce stress and anxiety for patients.

As well as promoting successful working of the facility's Medical Advisory Committee, Integrated Governance Committee and advising the hospital's senior management team on all matters relating to medical practice within the facility, Professor Ellis is responsible for providing advice on clinical governance matters to conform with national standards and recommend new programmes to drive up clinical standards.

In addition, he supports the HCA team to recruit and retain staff as well as taking a lead role in medical staff credentialing. In his role, he will evaluate ongoing quality initiatives such as clinical audits and quality assurance programmes.

Professor Ellis has also been heavily involved in developing the quality of breast cancer treatment by setting up an ongoing development of HCA patients in the Support/Living Well Programme. He also sits on the Chemotherapy executive board and continues to regularly lecture, as one of the medical experts, on each of the 10 week modules. In addition, he is the clinical lead for the LOC advisory group.

All services provided under this agreement are charged to HCA on an hourly basis as a rate of £274 per hour. This figure has been audited by market experts LaingBuisson and is considered fair market value.

HCA requires the doctors that advise us to attest that if they also practice in the NHS that they are not compromising their NHS commitments.

The information disclosed on this page in accordance with the Private Healthcare Market Investigation Order 2014 is true and accurate to the best of HCA’s knowledge and belief.